Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a serious life-threatening malignancy. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as Gefitinib and Erlotinib, are effective clinical medicines for advanced NSCLC patients harboring EGFR-activating mutations. However, this therapy ju...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Lei, Yang, Jiao, Cao, Zhixing, Chen, Xin, Hu, Yiguo, Li, Linli, Yang, Shengyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355060/
https://www.ncbi.nlm.nih.gov/pubmed/28086226
http://dx.doi.org/10.18632/oncotarget.14597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355060/
https://www.ncbi.nlm.nih.gov/pubmed/28086226
http://dx.doi.org/10.18632/oncotarget.14597

Ejemplares similares